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Background: Neuroblastoma, the most frequent solid extracranial tumor in children, is characterized by a wide spectrum of clinical behaviours.
We previously reported that high expression of somatostatin receptor type-2 (sst2) mRNA is associated to increased overall and event free
survival. Several genetic abnormalities are detected in neuroblastomas, frequently involving balanced and/or unbalanced gain on the long arm on
chromosome 17, the same region containing sst2 gene.
Methods: In this study we detected balanced and/or unbalanced 17q gain in 50 neuroblastomas. Since two polymorphisms in sst2 promoter
(−57 CNG and −83 ANG) were previously described as responsible for an in vitro reduction of sst2 mRNA expression, promoter sequencing
was also performed in the same samples. The results were compared to sst2 mRNA expression, measured by real-time RT-PCR.
Results: The frequency of 17q gain (14/50 neuroblastomas) was significantly associated to sst2 mRNA over-expression (Fischer's exact test:
p=0.0012). The sst2 expression was significant higher both in balance and unbalance 17q amplifications (ANOVA: p=0.04). Conversely, we
found a reduction of sst2 mRNA in neuroblastomas with −57 CNG promoter polymorphism (ANOVA: p=0.03).
Conclusion: We highlighted that 17q gain and promoter polymorphisms can play a role into the regulation of sst2 expression in neuroblastomas.
© 2007 Elsevier B.V. All rights reserved.Keywords: Balanced and unbalanced 17q gain; Multiplex real-time RT-PCR; Prognosis1. Introduction
Neuroblastoma is the most common solid extracranial
neoplasm in children and involves sympathetic nervous system
consisting of undifferentiated neural crest derived from
neuroectodermal cells. This tumor is characterized by different
clinical behaviours and clinical phenotypes, defined by a
complex pattern of genetic abnormalities [1]. Karyotypes of this
tumor frequently include many marker chromosomes and
unidentified products of unbalanced translocation, especially
in advanced stage of disease. Several genetic aberrations in⁎ Corresponding author. Clinical Biochemistry Units, Department of Clinical
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prognosis and their identification is important for patient
stratification, to select groups with high risk-level and then
adequate therapy [2].
The presence of structural abnormalities correlates with an
aggressive phenotype and frequently involves chromosomes 1p,
3p, 11q, 14q, 17q and MYCN amplification [2–4]. In particular,
rearrangements of chromosome 17, which were first described
in 1980s [5], seem to be a feature of considerable biological
significance. The prognostic relevance of 17q gain has been
confirmed by several authors [2,6,7]. It has been observed that
extra copies of the distal part of the long arm of chromosome 17
(17q gain) is the most frequent abnormality in neuroblastoma
cells, with an incidence ranging from 63 to 83% [7]. The role of
this genomic alteration in the progression of neuroblastoma is
still unclear. Some authors have found that the amplification of
the q-arm of chromosome 17, often resulting from an
unbalanced translocation der(1)t(1p;17q), is associated with
unfavourable prognosis in neuroblastoma suggesting that this
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in tumor progression, in particular in stage 4 of the disease [8].
A previous study, performed in a large series of neuroblastomas,
clarified the clinical significance of chromosome 17 amplifica-
tion [4]. In particular, the presence of balanced gain seems
predictive of a good patient outcome. Conversely, normal and
partial amplification of 17q are associated to worst prognosis,
particularly in patients with low-stage tumors.
We previously reported a study on the prognostic role of sst2
mRNA expression in neuroblastoma patients. Higher sst2
mRNA expression was related to positive overall and event
free survival, suggesting sst2 mRNA expression as a valid
factor to predict outcome, independently from MYCN ampli-
fication [9–11]. Nevertheless we observed that a group of
patients evidenced a worst prognosis, despite high sst2 mRNA
expression levels [9]. Antitumoral properties of sst2 have been
confirmed by several works. Somatostatin and its stable
analogues are able to suppress proliferation in normal and
tumor cells expressing somatostatin receptor [12]. Although no
mutations on sst2 gene (17q24) have been found in neuroblas-
toma [6], two polymorphisms of the sst2 promoter sequence
(−83 ANG and −57 CNG from the transcription initiation site)
have been described as negative transcription regulators in
pancreas cancer [13].
In the present study, we evaluated sst2 mRNA expression in
relation to 17q gain and sst2 promoter polymorphisms.
Balanced and unbalanced 17q gain were determined simulta-
neously by a novel triplex real-time PCR method.
2. Materials and methods
2.1. Tissues samples
The study group consisted of 50 (28 male and 22 female; mean age:
31 months; age range from 2 weeks to 198 months) neuroblastoma samples
obtained from the Italian Neuroblastoma Tissue Bank (Genoa, Italy).
Clinicopathological features of patients were assessed according to the
International Neuroblastoma Staging System (INSS) as follows: 11 patients
stage I (22%); 7 patients stage II (14%); 5 patients stage III (10%); 20 patients
stage IV (40%) and 7 patients stage 4s (14%). Cancer samples obtained from the
patients, were snap-frozen in liquid nitrogen; a sample of tumor tissue was
processed for routine histological examination. Informed consent of each
patients' parents was obtained.
2.2. Quantification of sst2 mRNA expression
For RNA extraction, tissues were disrupted by homogenisation in 600 μl of
guanidine isothiocyanate-containing lysis Qiagen buffer (QIAGEN S.p.A., Milan,
Italy) addedwithβ-merchaptoethanol. Total RNAwas extractedwith QIAshredder
and RNeasy MiniKit Qiagen® columns. RNAwas then eluted from columns with
50 μl of Qiagen® RNase free water. During the extraction process the sample was
treated with RNase free DNAse Set QIAGEN® to eliminate DNA. Quantification
of sst2 mRNA expression was performed with TaqMan technology as previously
reported [9,14]. The same cut-off value (7×107 molecules/μg total RNA)
previously defined [9] has been used to compare data obtained from genetic
analysis and expression pattern of sst2 mRNA.
2.3. DNA sequencing
The presence of polymorphism in the promoter region of sst2 (GenBank
Accession number: L34689) was evaluated in the 50 DNA from neuroblastomasand in 88 DNA extracted from whole blood of a normal population. Genomic
DNA was extracted from neoplastic tissues using a commercial kit, DNeasy
Tissue Kit (Qiagen S.p.A., Milan, Italy). DNA sequencing analysis was
performed as reported by Torrisani et al. [13]. Briefly, 100 ng of total DNA
were amplified in a PCR reaction mix of 25 μl of final volume. Samples were
treated for 9 min at 94 °C and to 35 cycles of amplification at 94 °C for 1 min,
60 °C for 1 min and 72 °C for 90 s. PCR products were purified and submitted to
cycle-sequencing reaction: 20 ng of DNA were blended with each primer
(0.8 μmol/l) in a Terminator Ready Reaction Mix containing Big Dye
Terminators (Applied Biosystems, Italy). Five microliters of marked and purified
DNA was submitted to sequencing analysis with ABI PRISM 310 Genetic
Analyser (Applied Biosystems, Italy).
2.4. Detection of chromosome 17 status by triplex real-time PCR
Balanced and unbalanced status of 17q have been defined by gene assay of
p53 and sst5 genes located in the short arm of chromosomes 17 and 16,
respectively. Since genetic abnormalities on p53 and sst5 gene have never been
described in neuroblastoma pathogenesis [15,16], these genes were used to
evaluate any amplification involving regions in the long arm of chromosome 17.
Sequences of the sst2 and sst5 were obtained from GenBank database.
Primers and TaqMan probes were designed using the proprietary software
“Primer Express” (PE, Applied Biosystems, Italy). For the amplification of the
intron-less gene sst2, primers and probe were the same described for mRNA
measurement [9]. Primers and probes selected for sst5 analysis were: forward
primer 5′-TCCTCTCCTACGCCAACAGC-3′, reverse primer 5′-GGAAGCT-
CTGGCGGAAGTT-3′ and probe 5′ (FAM)-CCCGTCCTCTACGGCTTCCT-
CTCTGA-(TAMRA) 3′. Primers and probe for p53 detection were the same as
used by T. Tajiri et al. [17].
The detection of sst2, sst5 and p53 DNA in each sample was made in triplicate
using differently labelled probes to perform a FAM (sst2)/VIC (p53)/TET (sst5)
assay in a triplex quantitative real-time PCR method with TaqMan technology.
TaqMan PCR was carried out using a reaction volume of 25 μl. One hundred
nanograms of DNAwere blended in a reaction mix containing 12.5 μl Universal
Master Mix 2X (Applied Biosystems, Italy), 200 nmol/l of each fluorescent probe,
300 nmol/l of each primer for sst2 and sst5 detection, 100 nmol/l of p53 primers.
The three differently labelled probes were added to the same reaction tube to
provide simultaneous measurement of the three genes. Samples were then
submitted to 2 min at 50 °C, 10 min at 95 °C and to 40 cycles of amplification at
95 °C for 15 s, 60 °C for 1 min in the ABI Prism 7700 Sequence Detector PE,
Applied Biosystems. As negative controls, each run included a duplicate tube
evaluation of “no template control” to exclude assay contamination. DNA
extracted from three neuroblastoma cell lines was used as positive controls: SH-
SY5Y,without 17q amplification, and SK-N-AS andLAN-5, bothwith unbalanced
17q gain [18].
Relationship between sst2, p53 and sst5 copy number was defined by
calculating 2−ΔΔCt, using a normal DNA as calibrator [19]. The ratios sst2/p53,
sst2/sst5 and p53/sst5 were calculated in the samples and in the calibrator, thus
defining three parameters related to the unbalanced (sst2/p53, sst2/sst5) and to
the balanced (sst2/sst5, p53/sst5) status (see Fig. 1).
To define the cut-off value for 17q gain determination, sst2/p53, sst2/sst5
and p53/sst5 ratios were evaluated in DNA from 20 normal control subjects.
The values of 2−ΔΔCt was calculated for each couple of genes. Relative ef-
ficiency of each reaction was calculated considering a standard curve generated
with a normal DNA, analyzed in a triplex assay (Fig. 1). For each gene, slope
value was obtained and used to define reaction efficiency by the formula:
e=10(−1 / slope)−1. Efficiencies were: sst2=1.08, p53=0.83 and sst5=0.85.
The respective cut-off values were obtained adding one standard deviation to
the mean, to guarantee the maximal specificity of the assays and adjusting
to the relative PCR efficiency [20] and were sst2/p53=1.5, sst2/sst5=1.8 and
p53/sst5=1.9.
2.5. Statistical analysis
Statistical analysis was carried out using the SPSS software package (SPSS
INC, Chicago, IL). Statistical differences between groups were assessed using
Fisher's exact test and ANOVA. Differences with pb0.05 were considered
statistically significant. To compare statistical difference between unbalanced
Fig. 1. Measurement of 17q copy number by triplex assay. A: Relationship between sst2, p53 and sst5 copy number and relative cut-off values adopted to evaluate 17q
unbalanced and balanced gain. Results obtained in 50 neuroblastoma are also reported. B: Linearity of the assays: Ct andΔCt values are compared to the concentration
of the starting quantity of DNA in each gene measured by triplex assay.
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cumulative survival in various subgroups was tested according to Kaplan–Meier
life tables and differences were tested with the log rank method.3. Results
3.1. Reliability of the triplex real-time PCR assay
To assess linearity of triplex assay, DNA extracted from
neuroblastoma cell lines SK-N-AS was serially diluted starting
from 100 ng to 10 pg and submitted to real-time PCR for the three
genes.As reported in Fig. 1, genes demonstrated a high parallelism,
independently from the concentration of the starting material.
Moreover, when considering theΔCt of each pair of genes for each
DNA concentration, we always obtained lines whose slope was as
close as possible to zero [19] (y=00105x+0.8795 for sst2/p53;
y=00078x+08807 for sst2/sst5; y=−00029x+1001 for p53/sst5).
The inter-assay reproducibility was evaluated in five triplex
assays, analyzing Ct values obtained from two controls: one
DNA from normal sample and one from LAN-5 cell line, as
reference of unbalanced 17q gain. Inter-assay reproducibility
calculated in the normal sample and in LAN-5 DNA was
respectively 2.31% and 4.18% (CV%) for sst2; 4.92% and
3.84% for p53, 3.73% and 5.35% for sst5. Intra-assayreproducibility was calculated from six replicates of DNA
from SK-N-AS samples; CV% values were: 0.79% for sst2,
1.84% for p53 and 2.09% for sst5.
3.2. 17q gain in neuroblastomas and absolute sst2 mRNA
expression
In 36/50 patients (72%), the sst2/p53, sst2/sst5 and p53/sst5
ratios were simultaneously in the range of normal controls,
indicating the absence of chromosome 17 abnormalities. In 9/50
neuroblastomas (18%) we found that sst2/p53 and sst2/sst5
ratios were simultaneously increased over the threshold (Fig. 1).
The presence, in the same patients, of a normal p53/sst5 ratio
indicated an amplification restricted to the long arm of
chromosome 17 and, therefore, an unbalanced gain. The
remaining 5 patients (10%) showed the amplification extended
to both arms (or even to the whole) of chromosome 17, as
evidenced from the increased sst2/sst5 and p53/sst5 ratios over
the threshold, but a normal sst2/p53 ratio.
A significant difference of sst2 mRNA expression was found
when our patients were classified on the basis of the absence
of 17q gain or of the presence of balanced and unbalanced
gain ( p=0.04, Fig. 2). In patients without evidence of 17q
modifications, sst2 mRNA expression was 5.8×108 ±2.0×108
Fig. 2. Expression of sst2 mRNA in 50 NB tumors, compared to 17q gain and to promoter polymorphisms. On the left: absolute values (mean±SD) of sst2 mRNA
levels in patients subdivided by 17q gain: no amplification, unbalanced and balanced gain. On the right: absolute values (mean) of sst2 mRNA in patients subdivided
by the presence of the promoter polymorphisms: homozygotes for wild type sequence, heterozygotes and homozygotes for −83 and −57 polymorphisms.
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patients with unbalanced and balanced gain, sst2 expression
was 4.2×109±2.9×109 and 2.0×109 ±7.4×108, respectively.
This latter difference was not significant. In patients with sst2
mRNA over-expression, unbalanced 17q gain is more frequent
(36%) in the group with unfavourable outcome than in those
with better prognosis (21%) even if this difference was not
statistically significant.
The probability of overall survival according to sst2
expression and 17q amplification, represented as Kaplan–
Meier curves, is reported in Fig. 3, confirming that patients with
high sst2 expression had a significantly better survival rate
(Fig. 3A, p=0.04). Considering 17q status we observed a 100%
of survival probability in patients with balanced gain, while
unbalanced amplification seems to be associated with unfavour-
able outcome (Fig. 3B). Furthermore, high sst2 mRNA ex-
pression levels are predictive of a good prognosis only in
patients without 17q aberrations (Fig. 3C). The last two differ-
ences were not statistically significant probably due to the low
number cases.Fig. 3. Overall survival probability in 50 patients with neuroblastoma according to sst
Meier curve shows the probability of survival in two groups of patients classified on
curve in patients subdivided on the basis of 17q gain status. C) Kaplan–Meier cur
presence of 17q aberration.3.3. −57 CNG and −83 ANG polymorphisms and absolute
sst2 mRNA expression
The −57 CNG polymorphism was detected in 23 subjects
as heterozygotes and in 21 as homozygotes (Table 1). In
neuroblastomas the allelic frequency of −57 (35% C and 65%
G) and −83 polymorphisms (76% A and 24% G) was similar to
those observed in our control population (40.2% C and 59.8% G
and 70.5% A and 29.5% G, respectively). However, we found
that the presence of sst2 promoter polymorphisms was
associated to a reduction of sst2 mRNA expression, both for
−83 and −57 variants. The level of sst2 mRNA expression in
wild type patients for −83 polymorphism (independently from
17q status) was 1.7×109 ±9.1×108, while in heterozygotes was
1.0×109±3.5×108 and in homozygotes 5.2×108 ±4.9×108.
In the case of −57 polymorphism, in wild type subjects sst2
expression was 5.2×109 ± 4.4× 109, significantly higher
(p=0.03) in comparison to heterozygotes and homozygotes
(7.9×108±3.03×108 and 9.4×108±2.94×108, respectively)
(Fig. 2).2 expression (left panel ) and 17q gain (central and right panel ). A)The Kaplan–
the basis of a reported cut-off (7×107 molecules/μg RNA). B) Kaplan–Meier
ve in patients with high sst2 mRNA expression subdivided on the basis of the
Table 1
Distribution of patients (n=50) on the basis of 17q amplification, promoter
polymorphism and sst2 mRNA expression





Not amplified 36 72 19 17
Unbalanced gain 9 18 1 8
Balanced gain 5 10 0 5 0.012
sst2 promoter polymorphism c
−57 CNG
Wild type 6 (16) 12 (18.2) 1 5
Heterozygotes 23 (39) 46 (44.3) 8 15
Homozygotes 21 (33) 42 (37.5) 11 10 N.S.
−83 ANG
Wild type 30 (49) 60 (55.7) 10 20
Heterozygotes 16 (26) 32 (29.5) 7 9
Homozygotes 4 (13) 8 (14.8) 3 1 N.S.
a Low and high expression of sst2 mRNA is determined considering the cut-
off value of 7×107 molecules/μg total RNA.
b The p value were calculated from Fisher's exact test and is significant when
b0.05.
c In brackets are reported the results obtained in our control population (n=88).
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As previously reported [9], we classified neuroblastoma
patients as expressing high or low sst2 mRNA according to a
biological cut-off (7×107 molecules/μg RNA). This cut-off was
previously determined as the threshold that separated the
somatostatin-responsive from unresponsive neuroblastoma cell
lines [21]. On this basis, sst2 mRNA expression can
discriminate patients with good prognosis (high expression)
from those with worse outcome (reduced expression). When our
group of neuroblastomas was stratified according to this cut-off,
we found that only 1/20 patients with low sst2 mRNA
expression had an unbalanced 17q gain, whereas 13/30 patients
with high sst2 had balanced or unbalanced gain. It is to note that
6 patients of this latter group had an adverse outcome (alive
with disease or dead of disease) in spite of the high sst2 mRNA
expression. Among the 20 patients with sst2 levels below the
cut-off, 10 of them had unfavourable outcome and none of them
had 17q gain.
In our group of neuroblastomas, 10 patients exhibit good
prognosis (absence of relapse with a mean follow-up of 73,
4months) in spite of the low sst2mRNAexpression. In this subset
we found a significant increase ( p=0.01) of −83 polymorphism
(80%) in comparison to the patients with expected adverse
prognosis (20%).
4. Discussion
Several studies performed in neuroblastoma tumors have
identified a common amplified region ranging from 17q21.3 to
17qter with a highly variable localization of the breakpoint
region [2,22]. Identification of one or more genes located in the
long arm of chromosome 17 is of large clinical interest since aneffect of their altered expression may be responsible for the
altered phenotype [23]. Most prominent candidate are the anti-
apoptotic regulatory genes: nm23-H1, -H2 and survivin. Nm23-
H1 and -H2 are members of a large family up regulated by
MYCN and c-MYC, thus accumulation of their mRNA levels
may be associated withMYCN amplification in tumors with 17q
gain [23]. Increased expression of survivin has been found to be
correlated significantly with adverse prognosis and outcome
[24,25] but direct correlation between extra copy of 17q and
gene expression in neuroblastoma has not yet been demonstrated
for this gene. Recently, extra copy numbers of 17q have been
correlated to WSB1 (17q11.1) gene expression [26].
The statement that the amplification of 17q may be an
independent predictor of disease outcome and the high
incidence in patients affected by neuroblastoma has reinforced
its identification in cytogenetics analysis. A PCR-based
approach in the detection of 17q amplification could make the
use of this parameter easier in defining tumor characteristic. A
validated duplex genomic real-time quantitative PCR assay has
been yet reported to evidence unbalanced status in neuroblas-
toma samples [27] suggesting the use of this method for a rapid
screening, but this approach fails to detect balanced gain of 17q,
equally responsible of an altered phenotype.
In this study we firstly investigated 17q amplification by
using a triplex assay method allowing a rapid determination of
both balanced and unbalanced status of chromosome amplifi-
cation. Further comparison of our results should be performed
with those obtained by approved techniques as FISH or CGH
before the method here described can be proposed as suitable
for diagnostic purposes. Results obtained in this work confirm
our previous study where sst2 mRNA measurement was
suggested as an independent prognostic marker in neuroblas-
toma [9], but also evidenced that a low number of subjects did
show high sst2 expression despite an advanced stage disease
and poor prognosis. Our hypothesis is that this apparent
contradiction depends upon genetic aspects, as amplification of
17q, that directly causes the increase of the copy number of sst2
gene, responsible of an altered expression pattern.
Data obtained by comparing 17q gain and sst2 levels seem to
confirm an association between the two parameters: 13/14
patients with 17q balanced or unbalanced amplification show
also high expression of sst2 mRNA. Even if sst2 mRNA
expression cannot be considered as a marker of 17q gain, the
amplification of the long arm of this chromosome seems to be
strictly related to an increase in its expression.
Interestingly, overall survival analysis showed that the whole
chromosome 17q gain is associated with favourable outcome,
while unbalanced gain confers poor prognosis, thus confirming
previously reported data [4].
Polymorphisms on sst2 promoter at position −83 ANG and
−57 CNG of the transcription initiation site were frequently
detected in pancreatic carcinoma. The −83 ANG has been found
to promote specific fixation of nuclear factor I (NF1) and thus
repression of sst2 mRNA transcription [13]. In our study, the
presence of sst2 promoter polymorphisms appeared not directly
related to neuroblastoma, since it was found in the normal popu-
lation with almost the same incidence. Nevertheless, a significant
154 L. Simi et al. / Clinica Chimica Acta 384 (2007) 149–154relationship between sequence for −57 variant and reduction in
sst2 mRNA levels was demonstrated. Furthermore, in the group
with good prognosis, polymorphism −83 is significantly
( p=0.01) related to low levels of sst2 mRNA expression.
Further study should be performed to evaluate other genetics
features which can be involved in sst2 expression in neuroblas-
toma as hypermethylation of CpG islands, microsatellites insta-
bility and chromosomal deletions.
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